Institution · Oregon Medical Research Center

Most cited papers from Oregon Medical Research Center

Oregon Medical Research Center

What are the most cited papers from Oregon Medical Research Center?

The most cited paper from Oregon Medical Research Center is "“Mini-mental state”" (Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh, 1975), with 87,598 citations. Next come "Trust as a Social Reality" (3,088) and "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis" (2,101).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 275 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	“Mini-mental state” Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research	Nov 1975	87,598
2	Trust as a Social Reality Jane Lewis, Andrew J. Weigert · Social Forces	Jun 1985	3,088
3	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis Eric Lawrence Simpson et al. · New England Journal of Medicine Open access	Oct 2016	2,101
4	Trust as a Social Reality J. David Lewis, Andrew J. Weigert · Social Forces	Jun 1985	2,029
5	Will Money Increase Subjective Well-Being? Ed Diener, Robert Biswas‐Diener · Social Indicators Research	Feb 2002	1,555
6	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Andrew Blauvelt et al. · The Lancet Open access	4 May 2017	1,269
7	Etanercept as Monotherapy in Patients with Psoriasis Craig L. Leonardi, JEROLD L. POWERS, Robert T. Matheson et al. · New England Journal of Medicine Open access	19 Nov 2003	1,188
8	Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis Craig L. Leonardi, Robert T. Matheson, Claus Otto Carl Zachariae et al. · New England Journal of Medicine Open access	28 Mar 2012	944
9	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Andrew Blauvelt, Kim Alexander Papp, Christopher E.M. Griffiths et al. · Journal of the American Academy of Dermatology Open access	4 Jan 2017	898
10	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Alexander Papp et al. · New England Journal of Medicine Open access	8 Jun 2016	855
11	Consensus guidelines for the detection of immunogenic cell death Oliver Kepp et al. · OncoImmunology Open access	2 Sep 2014	842
12	Types of Unintended Consequences Related to Computerized Provider Order Entry Emily M. Campbell, Dean F. Sittig, Joan S. Ash et al. · Journal of the American Medical Informatics Association Open access	23 Jun 2006	831
13	The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis Andrew Blauvelt, Andrea Chiricozzi · Clinical Reviews in Allergy & Immunology Open access	14 Aug 2018	794
14	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce E Strober, Mark Lebwohl et al. · The Lancet	Aug 2018	681
15	Rivers of Empire: Water, Aridity, and the Growth of the American West Lawrence Rakestraw, Donald Worster · Western Historical Quarterly	Jul 1987	639
16	Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* Andreas Wollenberg et al. · British Journal of Dermatology Open access	Oct 2020	627
17	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials Emma Guttman‐Yassky, Henrique D. Teixeira, Eric Lawrence Simpson et al. · The Lancet	20 May 2021	574
18	Imaging skin pathology with polarized light Steven L. Jacques, Jessica C. Ramella‐Roman, Ken Chi Lik Lee · Journal of Biomedical Optics Open access	2002	574
19	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial Diamant Thaçi et al. · The Lancet	20 Oct 2015	573
20	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Kristian Reich, Kim Alexander Papp, Andrew Blauvelt et al. · The Lancet	6 Jun 2017	565
21	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant Thaçi, Andrew Blauvelt, Kristian Reich et al. · Journal of the American Academy of Dermatology Open access	17 Jun 2015	550
22	Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis Claudia Maria Denkinger, Samuel G. Schumacher, Catharina C. Boehme et al. · European Respiratory Journal ReviewOpen access	2 Apr 2014	543
23	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis Eric Lawrence Simpson et al. · JAMA Dermatology Open access	6 Nov 2019	519
24	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis Kim Alexander Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine Open access	19 Apr 2017	516
25	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study Kenneth B. Gordon, Richard G B Langley, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology	11 Aug 2006	510
26	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, Henrique D. Teixeira, Eric Lawrence Simpson et al. · JAMA Dermatology Open access	4 Aug 2021	504
27	A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis Kim Alexander Papp, Kristian Reich, Carle F. Paul et al. · British Journal of Dermatology Open access	25 Feb 2016	470
28	First deuterated drug approved Charles W. Schmidt · Nature Biotechnology	Jun 2017	465
29	Hypothermia: Pathophysiology, Clinical Settings, and Management James B. Reuler · Annals of Internal Medicine	Oct 1978	450
30	Conjunctivitis in dupilumab clinical trials Bolanle K. Akinlade et al. · British Journal of Dermatology Open access	9 Mar 2019	433
31	Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years Janet T. Powell et al. · British journal of surgery ReviewOpen access714 authors	Feb 2017	432
32	Bimekizumab versus Secukinumab in Plaque Psoriasis Kristian Reich, Richard Bruce Warren, Mark Lebwohl et al. · New England Journal of Medicine	23 Apr 2021	427
33	Emergency Medical Services Intervals and Survival in Trauma: Assessment of the “Golden Hour” in a North American Prospective Cohort Craig D. Newgard, Robert H. Schmicker, Jerris R. Hedges et al. · Annals of Emergency Medicine Open access	24 Sep 2009	398
34	Randomized Study Evaluating Recombinant Human Bone Morphogenetic Protein‐2 for Extraction Socket Augmentation Joseph P. Fiorellini, T. Howard Howell, David Lee Cochran et al. · Journal of Periodontology	Apr 2005	390
35	CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells Debbie C. Strachan, Brian Ruffell, Yoko A. Oei et al. · OncoImmunology Open access	Dec 2013	383
36	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Kristian Reich, April Wang Armstrong, Richard G B Langley et al. · The Lancet	8 Aug 2019	382
37	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial April Wang Armstrong, Melinda Gooderham, Richard Bruce Warren et al. · Journal of the American Academy of Dermatology Open access	9 Jul 2022	371
38	The prevalence of atopic dermatitis in Oregon schoolchildren Diane Laughter, Joseph A. Istvan, Susan J. Tofte et al. · Journal of the American Academy of Dermatology	Oct 2000	370
39	Coding of somatic sensory input by vibrissae neurons in the rat's trigeminal ganglion Ellen Zucker, Wally I. Welker · Brain Research	1969	363
40	Practice parameter: Management of dementia (an evidence-based review) Barry Oken · Neurology	26 Dec 2001	352
41	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield et al. · JAMA Dermatology Open access	26 Feb 2020	345
42	Prospective, Multicenter Study of Spinal Cord Stimulation for Relief of Chronic Back and Extremity Pain Kim J. Burchiel, Valerie C. Anderson, Frederick D. Brown et al. · Spine	Dec 1996	342
43	Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis Jonathan I. Silverberg, Emma Guttman‐Yassky, Diamant Thaçi et al. · New England Journal of Medicine	15 Mar 2023	340
44	Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis Jack H. Simon et al. · Annals of Neurology	1998	335
45	Structural Studies of Aminoethylated Hemoglobins by Automatic Peptide Chromatography Richard T. Jones · Cold Spring Harbor Symposia on Quantitative Biology	1964	330
46	Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) Andrew Blauvelt, Jörg C. Prinz, Alice Bendix Gottlieb et al. · British Journal of Dermatology	16 Aug 2014	323
47	Available transfer capability calculations G.C. Ejebe, Jianzhong Tong, J. Waight et al. · IEEE Transactions on Power Systems	1998	321
48	Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard L. Sofen, STACY R. SMITH, Robert T. Matheson et al. · Journal of Allergy and Clinical Immunology Open access	28 Mar 2014	320
49	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial Kristian Reich, Kim Alexander Papp, Andrew Blauvelt et al. · The Lancet	Feb 2021	313
50	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai et al. · Journal of the American Academy of Dermatology	20 Sep 2016	312

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.